Clinical-grade quality platelet-rich plasma releasate (PRP-R/SRGF) from CaCl2-activated platelet concentrates promoted expansion of mesenchymal stromal cells

• Published in: Vox sanguinis 2016-08, Vol.111 (2), p.197-205
• Main Authors: Borghese, C., Agostini, F., Durante, C., Colombatti, A., Mazzucato, M., Aldinucci, D.
• Format: Article
• Language: English
• Subjects: Adipose Tissue - cytology; apheresis; Blood Platelets - cytology; Blood Platelets - drug effects; Blood Platelets - metabolism; Bone Marrow Cells - cytology; Calcium Chloride - pharmacology; Cell Differentiation; Cell Proliferation; Cells, Cultured; cellular therapy; cytokine; Cytokines - analysis; Enzyme-Linked Immunosorbent Assay; Humans; Intercellular Signaling Peptides and Proteins - analysis; mesenchymal stem cells; Mesenchymal Stromal Cells - cytology; Mesenchymal Stromal Cells - metabolism; Phenotype; platelet concentrates; Platelet-Rich Plasma - metabolism; Regenerative Medicine
• ISSN: 0042-9007; 1423-0410
• DOI: 10.1111/vox.12405

Background and Objectives The aim of our study was to test a platelet‐rich plasma releasate (PRP‐R/SRGF) from CaCl2‐activated platelets as a source of growth factors for the expansion of mesenchymal stromal cells (MSCs). PRP‐R/SRGF, obtained with a low‐cost procedure, is characterized by a reduced variability of growth factor release. Materials and Methods PRP‐R/SRGF is a clinical‐grade quality solution obtained from CaCl2‐activated platelets. Its activity was evaluated by measuring the proliferation, the phenotype, the differentiation potential and the immunosuppressive properties of MSCs derived from bone marrow (BM) and adipose tissue (AT). Results PRP‐R/SRGF was more active than FBS to expand BM‐ and AT‐derived MSCs. PRP‐R/SRGF treatment did not affect the expression of typical MSCs surface markers, neither MSCs differentiation potential nor their capability to inhibit activated T‐cell proliferation. Conclusions The clinical‐grade PRP‐R/SRGF may be used in the clinical setting for the expansion of MSCs.